Replies to post #191315 on Biotech Values

[ghmm]

GLPG / ABBV:

Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study

PR: http://www.glpg.com/files/6014/3820/0865/PR_Darwin1_24W_FINAL.pdf
Webcast: http://edge.media-server.com/m/p/jtbu3hgp
Slides: http://i.media-server.com/version/1438261847/m/a/3rczdbtq/iv/g9em5h2nx8q5rqp4r5pmvbhjdkzcypsth8ze6dmj3spqn74c_121598639/download

Didn't make notes yet but a Couple Comments from first listen:
1-Abbvie has 60 days from Darwin 2 ("any day") results to decide on licensing. Would "gladly" wave criteria requiring them to listen if they are not interested.
2-1 Death happened because of Pneumonia not clear if drug related as happened in hospital outside of investigator. 3 Weeks prior blood work was normal (nothing to show concern).
3-Not concerned with high dose in male patients. Monitored male hormone and no safety signal also in Darwin 3 much more males on high dose also did preclinical studies that think give freedom to operate.